FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

The Food and Drug Administration is warning that popular obesity drugs—including Ozempic, Wegovy, Zepbound, and Mounjaro—may carry a "potential increased risk" of a rare eye condition that can lead to permanent vision loss. In a drug safety…
Read the full story at Ars Technica ↗
ImpactNotable
Published3 d ago (Tue, 10 Nov 2026 14:43:49 GMT)
AuthorBeth Mole
MoreLess
Impact score33/100
RatingProbability of 46%.
RegionsGlobal
Retrievedvia rss
ClassifiedWed, 11 Nov 2026 00:02:58 GMT by classifier